Joly Hubert 4

What Happened Joly Hubert, a director of Johnson & Johnson (JNJ), received a grant of 975 Deferred Share Units (DSUs) on 2026-04-23. The transaction is reported as a derivative award with a reported price of $0.00 (total $0 on the Form 4) because the DSUs are deferred, cash‑settled compensation rather than an immediate stock purchase.

Key Details

• Transaction date: 2026-04-23; Form 4 filed: 2026-04-27 (filed within the typical 2 business‑day window).
• Reported amount: 975 DSUs; reported price: $0.00 (derivative award).
• Shares owned after transaction: not disclosed in the provided filing details.
• Footnotes: DSUs are granted under the Issuer’s Deferred Fee Plan and will be settled in cash upon termination of the director’s service (each DSU represents the fair market value of one JNJ share at settlement). The DSUs include dividend equivalent rights that accrue to the holder.
• Transaction type: A = Award/Grant (derivative, cash‑settled), not an open‑market buy or sale.

Context DSUs are a form of deferred compensation for directors. They do not transfer immediate voting rights or shares and are typically paid in cash (based on share price at settlement) when the director leaves the board. Such grants are routine compensation and are different from open‑market purchases (which may signal a director’s direct buying conviction).